| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | H D Ochs | |
| M Berger | |||
| R S Shapiro | |||
| R L Wasserman | |||
| S Misbah | |||
| M Borte | |||
| M H Sturzenegger | |||
| P2860 | cites work | Intravenous immunoglobulin for multifocal motor neuropathy | Q24247007 |
| Agammaglobulinemia | Q28244575 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy | Q33252355 | ||
| The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy | Q33332528 | ||
| Multifocal motor neuropathy with conduction block: a study of 24 patients | Q33734400 | ||
| EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases | Q34597256 | ||
| Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. | Q34699002 | ||
| Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. | Q34950507 | ||
| Immunoglobulin therapy: history, indications, and routes of administration | Q35685969 | ||
| Multifocal motor neuropathy: current concepts and controversies. | Q36072147 | ||
| Chronic inflammatory demyelinating polyneuropathy. | Q36084472 | ||
| Intravenous immunoglobulin in immunodeficiency states: state of the art. | Q36359664 | ||
| Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route | Q36777795 | ||
| Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study | Q36880697 | ||
| Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration | Q36903813 | ||
| Intravenous immunoglobulin: adverse reactions and management | Q37289504 | ||
| Subcutaneous administration of IgG. | Q37304911 | ||
| Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes | Q37304914 | ||
| Clinical uses of intravenous immune globulin. | Q37943411 | ||
| Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease | Q43839016 | ||
| Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs | Q44215065 | ||
| Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). | Q44386888 | ||
| Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion | Q44492893 | ||
| Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. | Q45985490 | ||
| Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study | Q46554901 | ||
| Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment | Q48536321 | ||
| Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study | Q49125609 | ||
| Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. | Q50784030 | ||
| How long is IVIg effective in multifocal motor neuropathy? | Q51021985 | ||
| Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. | Q51936602 | ||
| Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. | Q53901414 | ||
| Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy | Q60594481 | ||
| A recombinant human enzyme for enhanced interstitial transport of therapeutics | Q64377594 | ||
| Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency | Q71625240 | ||
| Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study | Q72335038 | ||
| Express subcutaneous IgG infusions: decreased time of delivery with maintained safety | Q74751746 | ||
| Consensus criteria for the diagnosis of multifocal motor neuropathy | Q78735138 | ||
| [Long-term follow-up of multifocal motor neuropathy with conduction block under intravenous immunoglobulin] | Q79783574 | ||
| Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies | Q80260138 | ||
| Hyaluronidase as a factor hastening the spread and absorption of water-soluble radiopaque substances deposited intracutaneously, subcutaneously and intramuscularly | Q80376156 | ||
| Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial | Q80454073 | ||
| Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance | Q80853169 | ||
| Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies | Q80874408 | ||
| Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home | Q82287317 | ||
| Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study | Q83940736 | ||
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 51-59 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Subcutaneous immunoglobulin: opportunities and outlook | |
| P478 | volume | 158 Suppl 1 |
| Q58083482 | A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement |
| Q38661420 | A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions? |
| Q48644044 | A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study |
| Q52564727 | An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland. |
| Q28743436 | Brown spider (Loxosceles genus) venom toxins: tools for biological purposes |
| Q89987141 | Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study |
| Q95272770 | Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review |
| Q37031111 | Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages". |
| Q86421371 | Dose and outcomes in primary immunodeficiency disorders |
| Q42237378 | Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency |
| Q48451728 | Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam®, in primary immunodeficiency |
| Q36121067 | Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. |
| Q40683402 | Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies |
| Q38021422 | Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis |
| Q38219946 | Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders |
| Q33692418 | II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies |
| Q38842992 | Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity |
| Q39067335 | Immunoglobulins: current understanding and future directions |
| Q33583520 | Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment |
| Q37666847 | Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry. |
| Q37877259 | Indications and safety of intravenous and subcutaneous immunoglobulin therapy |
| Q37083973 | Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency |
| Q89496397 | Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report |
| Q37962045 | Modern management of primary B-cell immunodeficiencies |
| Q42775420 | New Frontiers in Subcutaneous Immunoglobulin Treatment |
| Q38217591 | Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies |
| Q91786183 | Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency |
| Q37695737 | Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin |
| Q44921771 | Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein |
| Q64118161 | Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management |
| Q59127411 | Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management |
| Q38029244 | Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again |
| Q35580799 | Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model |
| Q40596658 | Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability |
| Q40066943 | Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases |
| Q44536209 | Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. |
| Q38798220 | Selecting a polyclonal immune globulin treatment for a patient with primary immune deficiency disease: Role of the clinical pharmacist |
| Q38122120 | Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. |
| Q38065205 | Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease |
| Q36617983 | Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer |
| Q37868757 | TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. |
| Q92428594 | The development and implementation of a subcutaneous immunoglobulin (SCIG) program at CancerCare Manitoba |
| Q57177417 | What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review |
| Q35560218 | What has happened in the last 50 years in immunology |
| Q92428540 | Élaboration et mise en place par ActionCancer Manitoba d’un programme d’administration d’immunoglobuline par voie sous-cutanée |
Search more.